Date: February 22, 2021
Sernova is developing therapeutics platform technologies to treat chronic diseases through a regenerative medicine approach. Further, the company's primary focus is the development of technologies for the treatment of patients with insulin-dependent (T1) diabetes, hemophilia A and thyroid disease.
The Cell Pouch™ is manufactured from medical-grade material. These materials have been previously approved by the FDA for permanent use in the body in other products. Moreover, Sernova’s Cell Pouch System™ is a novel implantable and scalable medical device. It forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells. These therapeutic cells release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs.
The Cell Pouch System™ combined with therapeutic cells can provide a convenient, safe and effective long-term therapeutic option for patients with chronic disease who seek to improve their quality of life. Additionally, the Cell Pouch™ is manufactured according to strict regulatory guidelines. It is also currently in clinical trials in patients with diabetes.
The Cell Pouch™ has been shown to form a biologically compatible site for therapeutic cells in humans.
For more information on Sernova Corp. (TSX.V: SVA, OTCQB: SEOVF) please fill out the form below.